Image credit: Nushin Rashidian

CBD’s Potential for Reproductive Harms Among “Big Reasons” Behind FDA’s Punt on Rules

The FDA is seeking a “harm reduction framework” as it works with Congress on a path for CBD, according to the agency’s Cannabis Product Committee lead.


Cronos exits US • Australia’s adult use push • UC Berkeley launches oral history series • & more …

An excerpt from recent editions of the Cannabis Wire Daily newsletter.

New York

New York’s Cannabis Equity Fund Recalibrates: “The Markets Have Changed” 

Cannabis regulators met on Tuesday for the second time in May to also approve emergency enforcement rules and a settlement related to a lawsuit that blocked licensing in parts of the state.